Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
5.67 EUR | -1.39% | +8.31% | -14.61% |
Apr. 03 | Nanobiotix completes escalation portion of 2020-0123 study | CF |
Apr. 02 | Nanobiotix Completes Dose Escalation Segment of Phase 1 Study Targeting Non-Small Cell Lung Cancer | MT |
Business Summary
The company's resources are primarily devoted to the development of its lead product candidate: NBTXR3, which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®.
Number of employees: 101
Managers
Managers | Title | Age | Since |
---|---|---|---|
Laurent Lévy
CEO | Chief Executive Officer | 53 | 03-03-03 |
Bart van Rhijn
DFI | Director of Finance/CFO | 52 | 21-05-31 |
Chief Tech/Sci/R&D Officer | - | 22-01-31 | |
Chief Tech/Sci/R&D Officer | - | 19-06-30 | |
Louis Kayitalire
CTO | Chief Tech/Sci/R&D Officer | 66 | 23-09-04 |
Craig West
IRC | Investor Relations Contact | - | - |
Human Resources Officer | 51 | 19-06-29 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Phillips
CHM | Chairman | 58 | 21-05-24 |
Enno Spillner
BRD | Director/Board Member | 55 | 14-06-17 |
Alain Herrera
BRD | Director/Board Member | 74 | 11-06-22 |
Director/Board Member | 62 | 13-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 35,230,382 | 35,083,775 ( 99.58 %) | 0 | 99.58 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.40% | 290M | |
+3.13% | 43.43B | |
+48.83% | 41.69B | |
+8.49% | 41.31B | |
-10.82% | 27.14B | |
+8.26% | 25.28B | |
-23.69% | 18.47B | |
+1.58% | 12.33B | |
+32.83% | 12.59B | |
+6.63% | 11.03B |
- Stock Market
- Equities
- NANO Stock
- Company Nanobiotix